New answers from the Prostate Cancer Prevention Trial on the chemoprevention of prostate cancer

Archivio Italiano di Urologia e Andrologia

Volumn 78, Issue 4, 2006, Pages 154-156

  Ankerst, Donna Pauler ^a,b   Thompson, Ian M ^a  

^a University of Texas Health Science Center   (United States)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

Chemoprevention; PCPT; Prostate cancer; PSA

Indexed keywords

FINASTERIDE; PLACEBO; PROSTATE SPECIFIC ANTIGEN;

BIOPSY; CANCER GRADING; CANCER PREVENTION; CHEMOPROPHYLAXIS; CONFERENCE PAPER; GLEASON SCORE; HUMAN; PROSTATE CANCER; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY; STATISTICAL ANALYSIS;

CLINICAL TRIALS; ENZYME INHIBITORS; FINASTERIDE; HUMANS; MALE; PROSTATIC NEOPLASMS;

EID: 33846289982     PISSN: 11243562     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (3)

1. Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003; 349: 215.
2. Ankerst DP, Thompson IM. Sensitivity and specificity of prostate-specific antigen for prostate cancer detection with high rates of biopsy verification, this volume.
3. Thompson IM, Chi C, Ankerst DP, et al. The effect of finasteride on the sensitivity of PSA for detecting prostate cancer. J Nat Canc Inst 2006; in press.